Sandra Dangelo is an Oncologist in New York, New York. Dangelo has been practicing medicine for over 19 years and is rated as an Elite expert by MediFind in the treatment of Merkel Cell Carcinoma. She is also highly rated in 35 other conditions, according to our data. Her top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Merkel Cell Carcinoma, Synovial Sarcoma, and Liver Embolization. She is licensed to treat patients in New York. Dangelo is currently accepting new patients.
Guilherme Rabinowits is a Hematologist Oncology specialist and an Oncologist in Miami, Florida. Rabinowits has been practicing medicine for over 23 years and is rated as an Elite expert by MediFind in the treatment of Merkel Cell Carcinoma. He is also highly rated in 15 other conditions, according to our data. His top areas of expertise are Merkel Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Tongue Cancer, and Squamous Cell Skin Carcinoma. He is licensed to treat patients in Florida. Rabinowits is currently accepting new patients.
Vernon Sondak is a General Surgeon in Tampa, Florida. Sondak has been practicing medicine for over 43 years and is rated as an Elite expert by MediFind in the treatment of Merkel Cell Carcinoma. He is also highly rated in 6 other conditions, according to our data. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Neuroendocrine Tumor, and Lymphofollicular Hyperplasia. He is licensed to treat patients in Florida. Sondak is currently accepting new patients.
Summary: This is a first-in-human (FIH), Phase 1, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors.
Summary: This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center